I mplantable 英 /ɪm'plæntəbəl/ 美 /ɪm'plæntəbl/
释义 adj. 可移植的，可植入的
例句 Objective: To summarize the implanting method and follow-up result of implantable cardioverter defibrillator(ICD).
cardioverter 英 /'kɑːdɪəʊ,vɜːtə/
释义 n. 心律转变器；复律器
例句 Amiodarone may be effective as an adjunct to implantable cardioverter-defibrillator therapy to reduce number of shocks.
Defibrillator 美 /di'fɪbrɪletɚ/
释义 n. 去纤颤器；电震发生器
例句 Some devices include a defibrillator，which gives a shock if the heart beats too fast.
作者： Samantha M McEvedy
Because of its high success rate in terminating ventricular tachycardia (VT) and ventricular fibrillation (VF) rapidly, along with the results of multiple clinical trials showing improvement in survival, implantable cardioverter-defibrillator (ICD) implantation is generally considered the first-line treatment option for the secondary prevention of sudden cardiac death (SCD) and for primary prevention in certain populations at high risk of SCD due to VT/VF. However, there are some situations in which ICD therapy is not recommended, including but not limited to patients with VT/VF from a completely reversible disorder and patients without a reasonable expectation of survival with an acceptable functional status for at least one year. The main indications for use of an ICD can be divided into two groups：Secondary prevention of sudden cardiac death (SCD) in patients with prior sustained ventricular tachycardia (VT), ventricular fibrillation (VF), or resuscitated SCD thought to be due to VT/VF；Primary prevention of SCD in patients at increased risk of life-threatening VT/VF. Primary prevention — Implantation of an ICD is recommended for the primary prevention of SCD due to life-threatening VT/VF in patients who have received optimal medical management (including use of beta blockers and angiotensin converting enzyme [ACE] inhibitors) yet remain at high risk of SCD, including: Patients with a prior MI (at least 40 days ago) and left ventricular ejection fraction (LVEF) ≤30 percent; Patients with a cardiomyopathy, New York Heart Association (NYHA) functional class II to III, and LVEF ≤35 percent. Patients with a nonischemic cardiomyopathy generally require optimal medical therapy for three months with documentation of persistent LVEF ≤35 percent at that time. Contemporary ICDs have extensive storage and monitoring capacities, the ability to deliver anti-tachycardia pacing (ie, overdrive pacing) to terminate VT, the ability to deliver synchronized and unsynchronized shocks for VT/VF, and the option of bradycardia pacing.